Key result
Clinical-proteomic model predicts post-pancreatitis diabetes, with elevated STC1 linked to ~9% greater pancreas fat.
Why the study?
Visceral and ectopic fat deposition are implicated in post-pancreatitis diabetes mellitus, but associated protein biomarkers and integrated prediction models required investigation.
Cohort
Yes
Odds Ratio: 1.09
p-value: p=0.011
A novel clinical-proteomic model incorporating a Lipid Metabolic Score, HbA1c, and STC1 significantly improves risk stratification for post-pancreatitis diabetes mellitus.
May aid post-pancreatitis diabetes prediction; leaves open whether STC1 modulation alters pancreas fat or incidence.
Introduction and Objective: Visceral and ectopic fat deposition are implicated in post-pancreatitis diabetes mellitus (PPDM-A). This study aimed to identify associated protein biomarkers and develop a novel prediction model by integrating cohort and proteomic data. Methods: We conducted an integrated analysis of clinical, imaging (CT-derived), and proteomic data from a Chinese cohort and the UK Biobank. A Lipid Metabolic Score (LMS) was constructed from several lipid metrics. Model performance was assessed by AUC. Causal inference for the lead protein (STC1) was evaluated via two-sample Mendelian randomization. Results: The LMS and recurrent pancreatitis were independent predictors of PPDM-A in the Chinese cohort. In the UK Biobank, a model combining baseline LMS and HbA1c achieved an AUC of 0.802 for PPDM-A prediction. Incorporating the protein STC1 enhanced the AUC to 0.861. Genetically elevated STC1 levels were causally associated with increased pancreas fat (OR = 1.09; P = 0.011). Conclusion: PPDM-A is driven by recurrent pancreatitis, dysglycemia, and lipid metabolism disorders mediated by visceral and ectopic fat. The proposed clinical-proteomic model, featuring STC1, significantly improves risk stratification and offers a potentially practical tool for early identification of high-risk patients. Disclosure Y. Wang: None. Funding National Natural Science Foundation of China (Grant Nos. 82470935)
No takes yet. Share an insight, caveat, or question.
Yi-Man Wang (2026) conducted a cohort in Post-pancreatitis diabetes mellitus (PPDM-A). Lipid Metabolic Score (LMS) and STC1 protein was evaluated on Increased pancreas fat (OR 1.09, p=0.011). A clinical-proteomic model incorporating a Lipid Metabolic Score, HbA1c, and STC1 predicted post-pancreatitis diabetes (AUC 0.861), and elevated STC1 increased pancreas fat (OR 1.09; P=0.011).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: